Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction–Associated Steatohepatitis (MASH)

Background & Aims: Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease that poses significant public health challenges. Although liver biopsy remains the gold standard for diagnostic and prognostic use in patients with MASH, its invasiveness limits its practical application in routine care and large-scale trials. This narrative review explores the growing role of noninvasive tests in the assessment of disease progression and treatment efficacy in MASH. Appr